Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma

Kimberly A. Clawson, Daniel Borja-Cacho, Mara B. Antonoff, Ashok Saluja, Selwyn M. Vickers

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Background: Cholangiocarcinoma originates from bile duct epithelial cells in the intrahepatic and extrahepatic biliary system. We recently observed that triptolide (a diterpenoid triepoxide) is effective in inducing apoptosis in pancreatic tumors. Death receptors 4 and 5 are overexpressed in several cancer types, and their activation by tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death. The principal objective of this study was to determine the effects of combination therapy with TRAIL and triptolide in cholangiocarcinoma. Materials and Methods: Two cholangiocarcinoma cell lines were incubated with various doses of triptolide and TRAIL, alone and in combination; cell viability was assessed at 24 and 48 h. Annexin-V staining and caspase-3 activity were measured after 24 h of triptolide, TRAIL or combination treatment. Western blots assessed protein levels of poly(ADP-ribose) polymerase (PARP) and X-linked inhibitor of apoptosis (XIAP). Results: Combination treatment using TRAIL and triptolide decreased cell viability in all cell lines at 48 h, with greater cell killing than that which was observed with either drug alone. This decrease in viability was associated with increases in annexin-V staining and caspase-3 activity. Western blot analysis demonstrated increases in PARP cleavage and decreases in XIAP expression that were dose-dependent. Conclusions: TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis. Furthermore, Western blot analysis suggests that triptolide sensitizes cells to TRAIL-induced apoptotic cell death by inhibiting expression of XIAP, a protein known to inhibit apoptosis. Our results demonstrate that combination of TRAIL and triptolide enhance apoptosis in cholangiocarcinoma cell lines.

Original languageEnglish (US)
Pages (from-to)244-249
Number of pages6
JournalJournal of Surgical Research
Volume163
Issue number2
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Tumor Necrosis Factor-alpha
Apoptosis
Ligands
TNF-Related Apoptosis-Inducing Ligand Receptors
Cell Survival
Poly(ADP-ribose) Polymerases
Annexin A5
Western Blotting
triptolide
Cell Line
Caspase 3
Cell Death
X-Linked Inhibitor of Apoptosis Protein
Staining and Labeling
Extrahepatic Bile Ducts
Diterpenes
Bile Ducts
Neoplasms

Keywords

  • apoptosis
  • cholangiocarcinoma
  • PARP
  • TRAIL
  • triptolide
  • XIAP

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. / Clawson, Kimberly A.; Borja-Cacho, Daniel; Antonoff, Mara B.; Saluja, Ashok; Vickers, Selwyn M.

In: Journal of Surgical Research, Vol. 163, No. 2, 01.10.2010, p. 244-249.

Research output: Contribution to journalArticle

Clawson, Kimberly A. ; Borja-Cacho, Daniel ; Antonoff, Mara B. ; Saluja, Ashok ; Vickers, Selwyn M. / Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. In: Journal of Surgical Research. 2010 ; Vol. 163, No. 2. pp. 244-249.
@article{426a79579434492885256a991bd10c20,
title = "Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma",
abstract = "Background: Cholangiocarcinoma originates from bile duct epithelial cells in the intrahepatic and extrahepatic biliary system. We recently observed that triptolide (a diterpenoid triepoxide) is effective in inducing apoptosis in pancreatic tumors. Death receptors 4 and 5 are overexpressed in several cancer types, and their activation by tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death. The principal objective of this study was to determine the effects of combination therapy with TRAIL and triptolide in cholangiocarcinoma. Materials and Methods: Two cholangiocarcinoma cell lines were incubated with various doses of triptolide and TRAIL, alone and in combination; cell viability was assessed at 24 and 48 h. Annexin-V staining and caspase-3 activity were measured after 24 h of triptolide, TRAIL or combination treatment. Western blots assessed protein levels of poly(ADP-ribose) polymerase (PARP) and X-linked inhibitor of apoptosis (XIAP). Results: Combination treatment using TRAIL and triptolide decreased cell viability in all cell lines at 48 h, with greater cell killing than that which was observed with either drug alone. This decrease in viability was associated with increases in annexin-V staining and caspase-3 activity. Western blot analysis demonstrated increases in PARP cleavage and decreases in XIAP expression that were dose-dependent. Conclusions: TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis. Furthermore, Western blot analysis suggests that triptolide sensitizes cells to TRAIL-induced apoptotic cell death by inhibiting expression of XIAP, a protein known to inhibit apoptosis. Our results demonstrate that combination of TRAIL and triptolide enhance apoptosis in cholangiocarcinoma cell lines.",
keywords = "apoptosis, cholangiocarcinoma, PARP, TRAIL, triptolide, XIAP",
author = "Clawson, {Kimberly A.} and Daniel Borja-Cacho and Antonoff, {Mara B.} and Ashok Saluja and Vickers, {Selwyn M.}",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.jss.2010.03.067",
language = "English (US)",
volume = "163",
pages = "244--249",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma

AU - Clawson, Kimberly A.

AU - Borja-Cacho, Daniel

AU - Antonoff, Mara B.

AU - Saluja, Ashok

AU - Vickers, Selwyn M.

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Background: Cholangiocarcinoma originates from bile duct epithelial cells in the intrahepatic and extrahepatic biliary system. We recently observed that triptolide (a diterpenoid triepoxide) is effective in inducing apoptosis in pancreatic tumors. Death receptors 4 and 5 are overexpressed in several cancer types, and their activation by tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death. The principal objective of this study was to determine the effects of combination therapy with TRAIL and triptolide in cholangiocarcinoma. Materials and Methods: Two cholangiocarcinoma cell lines were incubated with various doses of triptolide and TRAIL, alone and in combination; cell viability was assessed at 24 and 48 h. Annexin-V staining and caspase-3 activity were measured after 24 h of triptolide, TRAIL or combination treatment. Western blots assessed protein levels of poly(ADP-ribose) polymerase (PARP) and X-linked inhibitor of apoptosis (XIAP). Results: Combination treatment using TRAIL and triptolide decreased cell viability in all cell lines at 48 h, with greater cell killing than that which was observed with either drug alone. This decrease in viability was associated with increases in annexin-V staining and caspase-3 activity. Western blot analysis demonstrated increases in PARP cleavage and decreases in XIAP expression that were dose-dependent. Conclusions: TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis. Furthermore, Western blot analysis suggests that triptolide sensitizes cells to TRAIL-induced apoptotic cell death by inhibiting expression of XIAP, a protein known to inhibit apoptosis. Our results demonstrate that combination of TRAIL and triptolide enhance apoptosis in cholangiocarcinoma cell lines.

AB - Background: Cholangiocarcinoma originates from bile duct epithelial cells in the intrahepatic and extrahepatic biliary system. We recently observed that triptolide (a diterpenoid triepoxide) is effective in inducing apoptosis in pancreatic tumors. Death receptors 4 and 5 are overexpressed in several cancer types, and their activation by tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) induces cell death. The principal objective of this study was to determine the effects of combination therapy with TRAIL and triptolide in cholangiocarcinoma. Materials and Methods: Two cholangiocarcinoma cell lines were incubated with various doses of triptolide and TRAIL, alone and in combination; cell viability was assessed at 24 and 48 h. Annexin-V staining and caspase-3 activity were measured after 24 h of triptolide, TRAIL or combination treatment. Western blots assessed protein levels of poly(ADP-ribose) polymerase (PARP) and X-linked inhibitor of apoptosis (XIAP). Results: Combination treatment using TRAIL and triptolide decreased cell viability in all cell lines at 48 h, with greater cell killing than that which was observed with either drug alone. This decrease in viability was associated with increases in annexin-V staining and caspase-3 activity. Western blot analysis demonstrated increases in PARP cleavage and decreases in XIAP expression that were dose-dependent. Conclusions: TRAIL and triptolide in combination decreased cell viability and enhanced apoptosis. Furthermore, Western blot analysis suggests that triptolide sensitizes cells to TRAIL-induced apoptotic cell death by inhibiting expression of XIAP, a protein known to inhibit apoptosis. Our results demonstrate that combination of TRAIL and triptolide enhance apoptosis in cholangiocarcinoma cell lines.

KW - apoptosis

KW - cholangiocarcinoma

KW - PARP

KW - TRAIL

KW - triptolide

KW - XIAP

UR - http://www.scopus.com/inward/record.url?scp=77956901995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956901995&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2010.03.067

DO - 10.1016/j.jss.2010.03.067

M3 - Article

VL - 163

SP - 244

EP - 249

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -